J
Jens Kort
Researcher at AbbVie
Publications - 52
Citations - 1973
Jens Kort is an academic researcher from AbbVie. The author has contributed to research in topics: Glecaprevir & Pibrentasvir. The author has an hindex of 16, co-authored 45 publications receiving 1679 citations.
Papers
More filters
Journal ArticleDOI
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Stefan Zeuzem,Graham R. Foster,Stanley Wang,Armen Asatryan,Edward Gane,Jordan J. Feld,Tarik Asselah,Marc Bourlière,Peter Ruane,Heiner Wedemeyer,Stanislas Pol,Robert Flisiak,Fred Poordad,Wan-Long Chuang,Catherine A.M. Stedman,Steven L. Flamm,Paul Y. Kwo,Gregory J. Dore,Gladys Sepulveda-Arzola,Stuart K. Roberts,Ruth Soto-Malave,Kelly Kaita,Massimo Puoti,John M. Vierling,Edward Tam,Hugo E. Vargas,Rafi Bruck,Francisco Fuster,Seung-Woon Paik,Franco Felizarta,Jens Kort,Bo Fu,Ran Liu,Teresa I. Ng,Tami Pilot-Matias,Chih-Wei Lin,Roger Trinh,Federico J. Mensa +37 more
TL;DR: Once‐daily treatment with glecaprevir–pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
Journal ArticleDOI
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns,Samuel S. Lee,Joaquin Mario Valdes,Sabela Lens,Reem Ghalib,Humberto Aguilar,Franco Felizarta,Tarek Hassanein,Holger Hinrichsen,Diego Rincón,Rosa Maria Morillas,Stefan Zeuzem,Yves Horsmans,David R. Nelson,Yao Yu,Preethi Krishnan,Chih-Wei Lin,Jens Kort,Federico J. Mensa +18 more
TL;DR: The results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir achieved a sustained virological response at 12 weeks, and this drug regimen had a favourable safety profile in previously treated or untreated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis.
Journal ArticleDOI
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
Paul Y. Kwo,Fred Poordad,Armen Asatryan,Stanley Wang,David L. Wyles,Tarek Hassanein,Franco Felizarta,Mark S. Sulkowski,E.J. Gane,Benedict Maliakkal,J Scott Overcash,Stuart C. Gordon,Andrew J. Muir,Humberto Aguilar,Kosh Agarwal,Gregory J. Dore,C.-W. Lin,Ran Liu,Sandra S. Lovell,Teresa I. Ng,Jens Kort,Federico J. Mensa +21 more
TL;DR: Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations.
Journal ArticleDOI
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah,Kris V. Kowdley,Neddie Zadeikis,Stanley Wang,Tarek Hassanein,Yves Horsmans,Massimo Colombo,Filipe Calinas,Humberto Aguilar,Victor de Lédinghen,Parvez S. Mantry,Christophe Hézode,Rui Tato Marinho,Kosh Agarwal,Frederik Nevens,Magdy Elkhashab,Jens Kort,Ran Liu,Teresa I. Ng,Preethi Krishnan,C.-W. Lin,Federico J. Mensa +21 more
TL;DR: 8 weeks’ treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%.
Journal ArticleDOI
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
Fred Poordad,Franco Felizarta,Armen Asatryan,Mark S. Sulkowski,Robert Reindollar,Charles S. Landis,Stuart C. Gordon,Steven L. Flamm,Michael W. Fried,David E. Bernstein,C.-W. Lin,Ran Liu,Sandra S. Lovell,Teresa I. Ng,Jens Kort,Federico J. Mensa +15 more
TL;DR: The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA‐containing therapy; RBV coadministration did not improve efficacy.